Initial approaches with IGF-1 gene therapy in an animal model of parkinsonism associated to early cognitive impairments. Poster Session: 138. Shift 1. C6.d Cell, Molecular & Systems Biology: GCPR, dopamine & others receptors/ Short Talk

HERRERA M.; FALOMIR LOCKHART E; DOLCETTI FRANCO; CALFA G.; MOLINA V.; BELLINI M,; HEREÑÚ C.

Torino

Encuentro; Advances in Alzehimer´s and Parkinson´s Therapies and AAT-AD/PD Focus Meeting 2018; 2018

Advances in Alzehimer´s and Parkinson´s Therapies and AAT-AD/PD Focus Meeting 2018

Parkinson´s disease (PD) is a neurodegenerative disorder that results from a progressive dopaminergic neuronal loss. It is considered a multifactorial condition due to the multiplicity of symptoms experienced by patients. While this condition is known for its characteristic motor deficits, patients also have wide variety of non-motor symptoms, such as impaired learning and memory deficits, which severely affect their quality of life. These non-motor symptoms result from the dysfunction of interconnected systems, including the striatum, the neocortex and the hippocampus. Growth factors are new targets for therapeutical approaches. Insulin-like growth factor-1 (IGF-1) is an endogenous peptide transported across the blood brain barrier that is protective in several brain injury models, including in an animal model of parkinsonism.Objectives:1) To determine the early cognitive decline and the correlation of hippocampal changes in 6-OHDA model 2) To carry out therapeutic approaches with IGF-1 to understand plasticity processes in the neuronal activity of affected areas associated with cognitive decline.